登录
Top ten research priorities in global burns care: findings from the James Lind Alliance Global Burns Research Priority Setting Partnership [0.03%]
Hollie Sarah Richards,Robert M T Staruch,Suzannah Kinsella et al. Hollie Sarah Richards et al.
Burns are a global issue that can result in lifelong multimorbidities and disproportionately affect people in low-resource settings. Prioritising research of importance to patients and health-care professionals improves evidence-based care....
Aetiologies, neuroradiological features, and risk factors for mortality and long-term neurosequelae of febrile coma in Malawian children: a prospective cohort study [0.03%]
Stephen T J Ray,Charlotte E Fuller,Ajisa Ahmadu et al. Stephen T J Ray et al.
Background: Children in febrile coma in Africa are frequently hospitalised, with poorer outcomes than those in high-income settings. Cerebral malaria is historically the most common cause of febrile coma. Due to limited d...
The aetiologies, mortality, and disability of non-traumatic coma in African children: a systematic review and meta-analysis [0.03%]
Stephen T J Ray,Charlotte E Fuller,Alex Boubour et al. Stephen T J Ray et al.
Background: Non-traumatic coma in African children is a common life-threatening presentation often leading to hospital attendance. We aimed to estimate the distribution of non-traumatic coma causes and outcomes, including...
Symon M Kariuki,Charles R Newton Symon M Kariuki
The validity of test-negative design for assessment of typhoid conjugate vaccine protection: comparison of estimates by different study designs using data from a cluster-randomised controlled trial [0.03%] 基于群随机对照试验数据的不同研究设计估计值比较：检验阴性设计评估伤寒结合疫苗保护效力的有效性
Shuo Feng,Yiyuan Zhang,Farhana Khanam et al. Shuo Feng et al.
Background: Typhoid fever remains a substantial public health challenge in low-income and middle-income countries. By 2023, typhoid conjugate vaccines (TCVs) had been introduced in six countries globally, with more than 5...
Jane Ndungu Jane Ndungu
Live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in adults with or without M tuberculosis sensitisation: a single-centre, phase 1b-2a, double-blind, dose-escalation, randomised controlled trial [0.03%] 用于成人（无论是否对结核分枝杆菌致敏）的减毒结核分枝杆菌疫苗MTBVAC：一项一期b和二期a阶段、中心单臂、双盲剂量递增型随机对照试验
Angelique Kany Kany Luabeya,Virginie Rozot,Claire Imbratta et al. Angelique Kany Kany Luabeya et al.
Background: An effective adult vaccine is needed to control tuberculosis. We evaluated the safety and immunogenicity of a live-attenuated Mycobacterium tuberculosis vaccine (MTBVAC). ...
Diagnostic dilemmas and strain diversity in the MTBVAC phase 1b-2a trial in adults [0.03%] MTBVAC一期b二期a临床试验中的诊断难题和菌株多样性
Yanhua Liu,Wenping Gong Yanhua Liu